<< Back

Reata Pharmaceuticals, Inc. to Report Third Quarter 2018 Financial Results and Provide an Update on Development Programs on Wednesday, November 7, 2018

IRVING, Texas, Oct. 31, 2018 (GLOBE NEWSWIRE) — Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that the company will report third quarter 2018 financial results on Wednesday, November 7, 2018, before the U.S. financial markets open.  The company will host a conference call and live audio webcast at 8:00 a.m. ET on Wednesday, November 7, 2018, to discuss the financial results and provide an update on recent progress on its development programs.

Third quarter financial results to be discussed during the call will be included in an earnings press release that will be available on the company’s website shortly before the call at http://news.reatapharma.com and will be available for 12 months after the call.  The conference call can be accessed by dialing (844) 348-3946 (toll-free domestic) or (213) 358-0892 (international) and refer to conference ID 5199828.  The audio webcast can be accessed through the Investors & News section of the company’s website at http://reatapharma.com.  The webcast will be archived and available for replay on the company’s website for at least 90 days after the event.

About Reata Pharmaceuticals, Inc.

Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation.  Reata’s two most advanced clinical candidates, bardoxolone methyl and omaveloxolone, target the important transcription factor Nrf2 that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling.

Reata Pharmaceuticals, Inc.
(972) 865-2219

Investor Relations:
Vinny Jindal
Vice President, Strategy
(469) 374-8721

Matt Middleman, M.D.
LifeSci Public Relations
(646) 627-8384




Source: Reata Pharmaceuticals, Inc.